Clinical trials: Allergy; Dermatitis
Atopic Dermatitis
A Phase 2 Study of CIM331 for Atopic Dermatitis Patients
To assess the safety, tolerability and efficacy of CIM331, compared to placebo, in atopic dermatitis patients who are inadequately controlled by or intolerant to topical therapy
- Trial name
- NCT01986933
- Testing
- nemolizumab (CIM331)
- Where
- 18 sites in United States
- Volunteers
- 264 people
- Sponsor
- Chugai Pharmaceutical
Atopic Eczema/Dermatitis (Non-Specific)
Skin bioMARkers for Atopic Eczema Therapy Evaluation
The study aims to investigate two new non-invasive technologies for assessing skin properties to identify and validate a range of safety biomarkers that may be considered useful as primary outcome measures for evaluating the…
- Trial name
- SMART (NCT04194814)
- Testing
- crisaborole (2%) ointment, betamethasone valerate 0.1% cream
- Where
- United Kingdom
- Volunteers
- 37 people
- Sponsor
- Sheffield Teaching Hospitals NHS Foundation Trust
Dermatitis Atopic
Evaluation of Biomarkers of Atopic Dermatitis in Pediatric Patients (PEDISTAD BIOMARKER STUDY)
Primary Objective: To explore associations between biomarkers of atopic dermatitis (AD) and: Disease state and time course of AD, Disease state and evolution of selected atopic comorbid conditions, Effectiveness of specific AD…
- Trial name
- NCT03849716
- Testing
- Blood sample, Cheek swab
- Where
- 48 sites in United States, Argentina and 7 more
- Volunteers
- 266 people
- Sponsor
- Sanofi
Atopic Dermatitis
Tradipitant in Treatment-resistant Pruritus Associated With Atopic Dermatitis
This is a multicenter, randomized, double-blind, placebo-controlled study to be conducted in the United States in subjects with treatment-resistant pruritus diagnosed with atopic dermatitis.
- Trial name
- NCT02651714
- Testing
- Tradipitant
- Where
- 28 sites in United States
- Volunteers
- 168 people
- Sponsor
- Vanda Pharmaceuticals
Breast Cancer, Palmar-plantar Erythrodysesthesia
F511 Cream in Preventing Palmar-Plantar Erythrodysesthesia in Patients Receiving Doxorubicin Hydrochloride Liposome for Metastatic Breast Cancer
RATIONALE: F511 cream may prevent or reduce palmar-plantar erythrodysesthesia in women receiving doxorubicin hydrochloride liposome for metastatic breast cancer.
- Trial name
- NCT00992706
- Testing
- antiperspirant cream F511, pegylated liposomal doxorubicin hydrochloride
- Where
- 15 sites in Switzerland
- Volunteers
- 91 people
- Sponsor
- Swiss Cancer Institute
Atopic Dermatitis, Secondary Infection
Safety and Efficacy Study of Altabax Ointment in the Treatment of Secondarily Infected Atopic Dermatitis
Skin infections may complicate the treatment of atopic dermatitis.The use of topical ointments has become very important to avoid the use of oral antibiotics.
- Trial name
- NCT01064947
- Testing
- Retapamulin 1%
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Derm Research, PLLC
Atopic Dermatitis
Eczema Action Plan Improves Patient and Caregiver Understanding and Perception of Atopic Dermatitis Management
This is a randomized controlled study. The control group will consist of adult subjects and the caregivers of pediatric subjects with an established diagnosis of atopic dermatitis (AD), who are visiting a dermatologist for a…
- Trial name
- NCT01660217
- Testing
- A written Eczema Action Plan (EAP)
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Dermatology & Aesthetics of Wicker Park
Atopic Dermatitis
The Role of Filaggrin and FADS Genes on the Concentrations of PUFA Towards Its Effect on Atopic Dermatitis in Infants
The incidence of atopic dermatitis has increased dramatically in this years. Atopic dermatitis occurs due to complex interactions between genetic and environmental factors.
- Trial name
- FLG-FADSgen (NCT02401178)
- Where
- Indonesia
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Universitas Indonesia
Atopic Dermatitis, Atopic Dermatitis, Unspecified
Real World Efficiency of Abrocitinib Treatment at Patients With Moderate to Severe Atopic Dermatitis Who Had Inadequate Response to Previous Biologic Therapies.
This is a prospective, multi-center observational study characterizing clinical and patient reported outcomes of patients receiving abrocitinib for moderate-to-severe atopic dermatitis (M2S AD) who had inadequate response (or…
- Conditions
- Atopic Dermatitis, Atopic Dermatitis, Unspecified, Dermatitis, Atopic
- Trial name
- NCT06899204
- Testing
- Abrocitinib
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Pfizer
Atopic Dermatitis
Pharmacodynamics of Omiganan (CLS001) in Patients With Atopic Dermatitis
To assess the pharmacodynamics, safety/tolerability, and efficacy of omiganan in patients with mild to moderate atopic dermatitis (AD).
- Trial name
- NCT02456480
- Testing
- CLS001, Vehicle
- Where
- Netherlands
- Volunteers
- 37 people
- Sponsor
- Maruho Co., Ltd.
Atopic Dermatitis, Nummular Eczema
Chemokine Expression in Nummular Dermatitis and Atopic Dermatitis
The aim of this study is to measure the serum levels of CCL17, CCL18, CCL22 and CXCL10 and their expression levels in epidermis in AD and ND patients.
- Trial name
- NCT01311986
- Where
- Taiwan
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- National Taiwan University Hospital
Atopic Dermatitis (AD)
Treatment of Moderate-to-Severe Atopic Dermatitis With Ivarmacitinib in Adolescents and Adults
Atopic dermatitis (AD) is a skin condition characterized by a rash and itching, resulting from skin inflammation. Ivarmacitinib is an approved medication for treating AD.
- Trial name
- NCT07276620
- Testing
- Ivarmacitinib Sulfate Tablets
- Volunteers
- 1,000 people
- Sponsor
- Xiangya Hospital of Central South University
Atopic Dermatitis (AD)
Efficacy and Safety of Roflumilast Cream in Subjects With Atopic Dermatitis
This study will assess the safety and efficacy of Roflumilast cream versus vehicle applied once a day for 4 weeks by subjects with atopic dermatitis.
- Trial name
- NCT06631170
- Testing
- Roflumilast Cream 0.15%, Vehicle cream
- Where
- 61 sites in China
- Volunteers
- 354 people
- Sponsor
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Moderate-to-severe Atopic Dermatitis
The Study of CM326 in Patients With Moderate-to-severe Atopic Dermatitis
This is a multi-center, randomized, double blind, placebo-controlled multiple dose escalation study to evaluate the safety, tolerance, PK, PD, immunogenicity and preliminary efficacy of CM326 in moderate-severe AD subjects.
- Trial name
- NCT05186922
- Testing
- CM326
- Where
- China
- Volunteers
- 54 people
- Sponsor
- Keymed Biosciences Co.Ltd
Atopic Dermatitis, Healthy Volunteers
A Study to Evaluate Microneedle-based Collection of Dermal Interstitial Skin Fluid in Healthy Participants and Atopic Dermatitis Participants
The purpose of this study is to evaluate microneedle-based collection of dermal interstitial skin fluid (dISF) in healthy participants and atopic dermatitis (AD) participants
- Trial name
- NCT06934980
- Testing
- Microneedle Device
- Where
- Canada
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Incyte Corporation
Asthma
Use of a Probiotic Supplement to Prevent Asthma in Infants
The goal of the study is to understand the mechanisms of how antigen presentation affects the developing immune system and subsequently affects susceptibility to, or protects against, asthma development.
- Trial name
- NCT00113659
- Testing
- Probiotic
- Where
- United States
- Volunteers
- 203 people, healthy volunteers welcome
- Sponsor
- Montefiore Medical Center
Atopic Dermatitis (AD)
Real World Study of Oral Upadacitinib Tablets to Assess Adverse Events and Change in Disease Activity in Adolescent and Adult Chinese Participants With Atopic Dermatitis
Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. This study will assess how safe and effective upadacitinib is in treating AD in adolescent and adult Chinese…
- Trial name
- NCT05959083
- Where
- 18 sites in China
- Volunteers
- 200 people
- Sponsor
- AbbVie
Atopic Dermatitis
A Study to Assess the Efficacy and Safety of Afimkibart (RO7790121) in Participants With Moderate to Severe Atopic Dermatitis
The purpose of this study is to assess the efficacy and safety of Afimkibart (also known as RO7790121) in participants with moderate to severe atopic dermatitis (AD).
- Trial name
- NCT06863961
- Testing
- Afimkibart
- Where
- 60 sites in United States, Brazil and 6 more
- Volunteers
- 162 people
- Sponsor
- Hoffmann-La Roche
Atopic Dermatitis
Drug Survival of Target Therapies in Atopic Dermatitis
This is an observational study with drug to evaluate the drug survival of approved target therapies in atopic dermatitis. Patients affected by moderate-severe atopic dermatitis who will start therapy with approved target drugs…
- Trial name
- VADRUDA (NCT06882148)
- Testing
- target therapies (biological drug, small molecules)
- Where
- Italy
- Volunteers
- 1,167 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Atopic Dermatitis
Dupilumab Phase 4 Study
The investigators will monitor for the incidence of adverse-events in a prospective, longitudinal, non-interventional and observational real-world sub-study of adults patients with moderate-to-severe AD who are receiving…
- Trial name
- DRS (NCT03411837)
- Testing
- Dupilumab
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- Northwestern University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.